Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
81% more capital invested
Capital invested by funds: $121M → $219M (+$97.8M)
23% more funds holding
Funds holding: 40 → 49 (+9)
2.34% more ownership
Funds ownership: 7.02% → 9.36% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$10.1M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$9.38M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$5.21M |
| 4 |
O
OrbiMed
New York
|
+$5.21M |
| 5 |
Axa
Paris,
France
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$418K |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$405K |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$387K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$219K |
ADAP Hedge Fund Activity: Q1 2017 in Review
49 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2017, worth a combined $219M — up 81% from $121M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADAP positions and 7 closed out — a net gain of 9 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Capital World Investors, adding an estimated $10.1M. The largest seller was Fidelity Investments, cutting an estimated $3.43M.
- 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2017, up from 40 in Q4 2016.
- Funds reported $219M of Adaptimmune Therapeutics stock for Q1 2017, up 81% quarter-over-quarter.
- 16 funds opened new Adaptimmune Therapeutics positions in Q1 2017 and 7 closed out, a net change of +9 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2017 was Capital World Investors, an estimated $10.1M added.
- The largest Adaptimmune Therapeutics seller in Q1 2017 was Fidelity Investments, an estimated $3.43M sold.
Based on aggregated 13F filings for Q1 2017.